- Home
- PMVP vs EDAP Comparison
PMVP vs EDAP Comparison
Compare PMVP & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | EDAP |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 75.5M |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | PMVP | EDAP |
|---|---|---|
| Price | $1.24 | $3.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 269.9K | 67.0K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $74,853,925.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.61 |
| 52 Week Low | $0.81 | $1.21 |
| 52 Week High | $1.84 | $3.45 |
Technical Indicators
Market Signals| Indicator | PMVP | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 67.51 |
| Support Level | $1.20 | $2.70 |
| Resistance Level | $1.25 | $3.00 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 70.27 | 91.13 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.